Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study

Sponsor
Amsterdam UMC, location VUmc
Study ID
NCT01190241
Status
Terminated

Conditions

  • Advanced Solid Tumors
  • Inoperable
  • Metastasis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to select targeted treatment based on ex vivo kinase activity inhibition profiles to targeted agents of tumor tissue from patients with advanced cancer for whom no standard treatment is available.

Key Dates

First listed
Aug 27, 2010
Start date
Aug 31, 2010
Status verified
Nov 2020
Primary completion
Dec 31, 2017
Completion
Dec 31, 2017

Study Design

Enrollment
45 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Targeted treatment
    Targeted treatment with desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib

Primary Outcome Measure

The clinical benefit rate (CBR) of this therapy selection approach. [ Time Frame: 12 weeks ]

Related Studies